These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 27787908)

  • 21. The diagnosis of hypovascular hepatic lesions showing hypo-intensity in the hepatobiliary phase of Gd-EOB- DTPA-enhanced MR imaging in high-risk patients for hepatocellular carcinoma.
    Nakamura S; Nouso K; Kobayashi Y; Shiraha H; Ohnishi H; Toshimori J; Kuwaki K; Hagihara H; Takayama H; Yamamoto K
    Acta Med Okayama; 2013; 67(4):239-44. PubMed ID: 23970322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.
    Inoue T; Kudo M; Komuta M; Hayaishi S; Ueda T; Takita M; Kitai S; Hatanaka K; Yada N; Hagiwara S; Chung H; Sakurai T; Ueshima K; Sakamoto M; Maenishi O; Hyodo T; Okada M; Kumano S; Murakami T
    J Gastroenterol; 2012 Sep; 47(9):1036-47. PubMed ID: 22526270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
    Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
    Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease.
    Takechi M; Tsuda T; Yoshioka S; Murata S; Tanaka H; Hirooka M; Mochizuki T
    Jpn J Radiol; 2012 Nov; 30(9):743-51. PubMed ID: 23001373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.
    Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1309-1316. PubMed ID: 33896023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypovascular hypointense nodules on hepatobiliary phase without T2 hyperintensity on gadoxetic acid-enhanced MR images in patients with chronic liver disease: long-term outcomes and risk factors for hypervascular transformation.
    Kim YS; Song JS; Lee HK; Han YM
    Eur Radiol; 2016 Oct; 26(10):3728-36. PubMed ID: 26670318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differences in the Diagnosis and Treatment of Patients with Early-Stage Hepatocellular Liver Cancer by Multi-Row Spiral CTMDCT and Gd-EOB-DTPA-Enhanced MRI.
    Wang K; Jin X; Zhou J; Wang Z; Zhang X
    Altern Ther Health Med; 2024 Jan; 30(1):31-35. PubMed ID: 37773658
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma.
    Ichikawa S; Ichikawa T; Motosugi U; Sano K; Morisaka H; Enomoto N; Matsuda M; Fujii H; Araki T
    J Magn Reson Imaging; 2014 Feb; 39(2):293-7. PubMed ID: 23633285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma.
    Ariizumi S; Kitagawa K; Kotera Y; Takahashi Y; Katagiri S; Kuwatsuru R; Yamamoto M
    J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):575-85. PubMed ID: 21360083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological significance of the peritumoral decreased uptake area of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid in hepatocellular carcinoma.
    Nishie A; Asayama Y; Ishigami K; Kakihara D; Nakayama T; Ushijima Y; Takayama Y; Shirabe K; Fujita N; Kubo Y; Hirakawa M; Honda H
    J Gastroenterol Hepatol; 2014 Mar; 29(3):561-7. PubMed ID: 24219648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct-Acting Antiviral Agents Reduce the Risk of Malignant Transformation of Hepatobiliary Phase-Hypointense Nodule without Arterial Phase Hyperenhancement to Hepatocellular Carcinoma on Gd-EOB-DPTA-Enhanced Imaging in the Hepatitis C Virus-Infected Liver.
    Shimizu Y; Arai K; Yamashita T; Yamashita T; Shimakami T; Kawaguchi K; Kitamura K; Sakai Y; Mizukoshi E; Honda M; Kitao A; Kozaka K; Kobayashi S; Kaneko S
    Liver Cancer; 2020 Jun; 9(3):261-274. PubMed ID: 32647630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of the suitable candidates for EOB-MRI with the high risk of the presence of non-hypervascular hypointense nodules in patients with HCV infection.
    Toyoda H; Yasuda S; Shiota S; Sone Y; Maeda A; Kaneoka Y; Kumada T; Tanaka J
    Eur Radiol; 2022 Jul; 32(7):5016-5023. PubMed ID: 35142900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between signal intensity on hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriaminepentaacetic acid (Gd-EOB-DTPA)-enhanced MR imaging and prognosis of borderline lesions of hepatocellular carcinoma.
    Kobayashi S; Matsui O; Gabata T; Koda W; Minami T; Ryu Y; Kozaka K; Kitao A
    Eur J Radiol; 2012 Nov; 81(11):3002-9. PubMed ID: 22748558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fusion imaging with contrast-enhanced ultrasonography for evaluating the early therapeutic efficacy of radiofrequency ablation for small hypervascular hepatocellular carcinomas with iso-echoic or unclear margins on conventional ultrasonography.
    Nishigori S; Numata K; Irie K; Fukuda H; Chuma M; Maeda S
    J Med Ultrason (2001); 2018 Jul; 45(3):405-415. PubMed ID: 29362966
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Focal lesions in the cirrhotic liver: their pivotal role in gadoxetic acid-enhanced MRI and recognition by the Western guidelines.
    Golfieri R; Garzillo G; Ascanio S; Renzulli M
    Dig Dis; 2014; 32(6):696-704. PubMed ID: 25376286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging.
    Kanefuji T; Takano T; Suda T; Akazawa K; Yokoo T; Kamimura H; Kamimura K; Tsuchiya A; Takamura M; Kawai H; Yamagiwa S; Aoyama H; Nomoto M; Terai S
    World J Gastroenterol; 2015 Apr; 21(15):4583-91. PubMed ID: 25914467
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma.
    Yoo SH; Choi JY; Jang JW; Bae SH; Yoon SK; Kim DG; Yoo YK; Rha SE; Lee YJ; Jung ES
    Ann Surg Oncol; 2013 Sep; 20(9):2893-900. PubMed ID: 23649931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-hypervascular Hypointense Nodules on Hepatocyte Phase Gadoxetic Acid-Enhanced MR Images: Transformation of MR Hepatobiliary Hypointense Nodules into Hypervascular Hepatocellular Carcinomas.
    Cho YK; Kim JW; Kim MY; Cho HJ
    Gut Liver; 2018 Jan; 12(1):79-85. PubMed ID: 28798287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative evaluation of three-dimensional Gd-EOB-DTPA-enhanced MR fusion imaging with CT fusion imaging in the assessment of treatment effect of radiofrequency ablation of hepatocellular carcinoma.
    Makino Y; Imai Y; Igura T; Hori M; Fukuda K; Sawai Y; Kogita S; Fujita N; Takehara T; Murakami T
    Abdom Imaging; 2015 Jan; 40(1):102-11. PubMed ID: 25052767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma.
    Aoki T; Nishida N; Ueshima K; Morita M; Chishina H; Takita M; Hagiwara S; Ida H; Minami Y; Yamada A; Sofue K; Tsurusaki M; Kudo M
    Liver Cancer; 2021 Nov; 10(6):615-628. PubMed ID: 34950184
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.